Get the Stockscreener App
0.729
2.68%
0.019
After Hours:
.73
0.001
+0.14%
Dermata Therapeutics Inc stock is traded at $0.729, with a volume of 43,601.
It is up +2.68% in the last 24 hours and down -37.69% over the past month.
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
See More
Previous Close:
$0.71
Open:
$0.72
24h Volume:
43,601
Relative Volume:
0.03
Market Cap:
$4.40M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.034
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-7.49%
1M Performance:
-37.69%
6M Performance:
-53.86%
1Y Performance:
-83.52%
1-Day Range:
$0.70
$0.73
1-Week Range:
$0.70
$0.8901
52-Week Range:
$0.70
$6.171
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.729 | 4.40M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia
Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa
Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus
Dermata Therapeutics IncAnnounces Topline Results From Phase 3 Trial Of XyngariSEC Filing - marketscreener.com
Dermata reports early success in acne treatment with XYNGARI - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World
Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada
Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Dermata Therapeutics stock hits 52-week low at $1 - Investing.com
Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus
Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph
XYNGARI shows promise in Phase 3 acne trial By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results - Investing.com
Dermata's XYNGARI(TM) Phase 3 Trial Topline Data Meets All Primary Endpoints - MarketScreener
XYNGARI shows promise in Phase 3 acne trial - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Breakthrough in Phase 3 Trial - Stock Titan
Dermata Therapeutics Faces Nasdaq Delisting Notice By Investing.com - Investing.com India
Dermata Therapeutics Faces Nasdaq Delisting Notice - Investing.com
Dermata Therapeutics, Inc. SEC 10-K Report - TradingView
Major Catalyst Alert: Dermata's Phase 3 Acne Treatment Results Coming in Weeks - StockTitan
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR
Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail
Head-To-Head Analysis: Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) - The AM Reporter
Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World
Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com
Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne - PR Newswire
Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR
Papulopustular Rosacea Clinical and Non-Clinical Studies, Key - openPR
APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis - MSN
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
DRMADermata Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):